Vera Therapeutics announces FDA alignment on earlier eGFR analysis for atacicept; results expected Q3 2026

Vera Therapeutics, Inc.

FDA agreed to revised ORIGIN 3 eGFR analysis plan to support potential full approval of atacicept in IgA Nephropathy.
eGFR results now expected in the third quarter of 2026.
Company plans to submit supplemental Biologics License Application for full approval in Q4 2026.
Alignment could accelerate path to full approval for atacicept.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.